221 Glaucoma - Tips, consejos y experiencias 17. Osborne SA, Montgomery DM, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond) 2005;19(2):129–137. 18. Wirtitsch MG, Findl O, Heinzl H, Drexler W. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol. 2007;125(10):1345–1350. 19. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327–335. 20. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82(1):39–42. 21. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109–115. 22. Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: A review. Open Ophthalmol J. 2014;8(1):67–72. 23. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: Associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3):93–103. 24. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. 25. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5):490–496. 26. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. 27. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147(4):725–735.e1. 28. Saade CE, Lari HB, Berezina TL, Fechtner RD, Khouri AS. Topical glaucoma therapy and ocular surface disease: A prospective, controlled cohort study. Can J Ophthalmol. 2015;50(2):132–136. 29. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–621. 30. Gulati A, Sullivan R, Buring JE, Sullivan DA, Dana R, Schaumberg DA. Validation and repeatability of a short questionnaire for dry eye syndrome. Am J Ophthalmol. 2006;142(1):125–131 31. Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular surface disease in glaucoma: Effect of polypharmacy and preservatives. Optom Vis Sci. 2015;92(9):e222–e226. 32. 32.- Szakats I, Sebestyen M, Nemeth J, Birkas E, Purebl G. The role of health anxiety and depressive symptoms in dry eye disease. Curr Eye Res. 2016;41(8):1044–1049. 33. Li M, Gong L, Sun X, Chapin W. Anxiety and depression in patients with dry eye syndrome. Curr Eye Res. 2011;36(1):1–7. 34. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1593–1601. 35. Kocabeyoglu S, Mocan MC, Irkec M, Orhan M, Karakaya J. Conjunctivochalasis as a contributing factor for the development of ocular surface disease in medically treated glaucoma patients. J Glaucoma. 2014;23(5):333–336. 36. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservativefree glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349. 37. Justiniano MJ, Loew P. 38. Lee SY, Wong TT, Chua J, Boo C, Soh YF, Tong L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye (Lond) 2013;27(10):1142–1150. 39. Sezgin Akcay BI, Guney E, Bozkurt TK, Topal CS, Akkan JC, Unlu C. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: An impression cytology study. J Ocul Pharmacol Ther. 2014;30(7):548–553. 40. Yamazaki S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54(1):7–14. 41. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2(3):613–621. 42. Gazzard G, Konstantakopoulou E, Garway-Heath D, Barton K, Wormald R, Morris S, Hunter R, Rubin G, Buszewicz M, Ambler G, Bunce C; LiGHT Trial Study Group. Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology. Br J Ophthalmol. 2018 May;102(5):593-598. 43. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Fernandez-Perez C, Garcia-Sanchez J, Garcia-Feijoo J. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: A long-term study. Br J Ophthalmol. 2012;96(5):645–649. 44. Hoeh H, Ahmed II, Grisanti S, et al. Early postoperative safety and surgical outcomes after implantation of a suprachoroidal microstent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg. 2013;39(3):431–437. 45. Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study. J Ocul Pharmacol Ther. 2015;31(6):323–329. 46. Liu X, Yu FF, Zhong YM, Guo XX, Mao Z. Therapeutic effects of sodium hyaluronate on ocular surface damage induced by benzalkonium chloride preserved anti-glaucoma medications. Chin Med J (Engl) 2015;128(18):2444–2449. 47. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181–184
RkJQdWJsaXNoZXIy MTYwMjk1